A Raniszewska1, H Vroman2, D Dumoulin3, R Cornelissen3, J G J V Aerts3, J Domagała-Kulawik4. 1. Department of Pathology, Medical University of Warsaw, Pawinskiego 7 Street, 02-106, Warsaw, Poland. 2. Department of Pulmonary Medicine, Erasmus MC Cancer Institute, s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. h.vroman@erasmusmc.nl. 3. Department of Pulmonary Medicine, Erasmus MC Cancer Institute, s-Gravendijkwal 230, 3015 CE, Rotterdam, The Netherlands. 4. Department of Internal Medicine, Pulmonary Diseases and Allergy, Medical University of Warsaw, Banacha 1a Street, 02-097, Warsaw, Poland.
Abstract
INTRODUCTION: Cancer stem cells (CSCs) are implicated in tumor initiation and development of metastasis. However, whether CSCs also affect the immune system is not fully understood. We investigated correlations between the PD-L1+ CSCs, changes in T-cell phenotype in metastatic and non-metastatic lymph nodes (LNs) and response to treatment. METHODS: LNs' aspirates were obtained during the EBUS/TBNA procedure of 20 NSCLC patients at different stages of the disease. CSCs and T-cell characteristics were determined by flow cytometry. RESULTS: PD-L1+ CSCs positively correlated with the percentage of Tregs, PD-1+ CD4 T cells and Tim3+ CD4+ T cells, whereas PD-L1+ CSCs were negatively correlated with CD4+ T cells and CD28+ CD4+ T cells. The percentage of PD-L1+ CSCs was higher in patients with progressive disease (PD) as compared to patients with stable disease (SD) or partial response (PR). Among T cells, only PD-1+ CD4+ T cells and Tim3+ CD4+ T-cell frequencies were higher in patients with PD as compared to patients with SD or PR. CONCLUSION: The frequency of PD-L1+ CSCs associates with an altered T-cell frequency and phenotype indicating that CSCs can affect the immune system. The higher percentage of PD-L1+ CSCs in patients with PD may confirm their resistance to conventional therapy, suggesting that CSCs may be an interesting target for immunotherapy.
INTRODUCTION:Cancer stem cells (CSCs) are implicated in tumor initiation and development of metastasis. However, whether CSCs also affect the immune system is not fully understood. We investigated correlations between the PD-L1+ CSCs, changes in T-cell phenotype in metastatic and non-metastatic lymph nodes (LNs) and response to treatment. METHODS:LNs' aspirates were obtained during the EBUS/TBNA procedure of 20 NSCLCpatients at different stages of the disease. CSCs and T-cell characteristics were determined by flow cytometry. RESULTS:PD-L1+ CSCs positively correlated with the percentage of Tregs, PD-1+ CD4 T cells and Tim3+ CD4+ T cells, whereas PD-L1+ CSCs were negatively correlated with CD4+ T cells and CD28+ CD4+ T cells. The percentage of PD-L1+ CSCs was higher in patients with progressive disease (PD) as compared to patients with stable disease (SD) or partial response (PR). Among T cells, only PD-1+ CD4+ T cells and Tim3+ CD4+ T-cell frequencies were higher in patients with PD as compared to patients with SD or PR. CONCLUSION: The frequency of PD-L1+ CSCs associates with an altered T-cell frequency and phenotype indicating that CSCs can affect the immune system. The higher percentage of PD-L1+ CSCs in patients with PD may confirm their resistance to conventional therapy, suggesting that CSCs may be an interesting target for immunotherapy.
Entities:
Keywords:
Cancer stem cells; EBUS/TBNA; Lung cancer; Lymph nodes; T cells
Authors: Antonio Bugalho; Catarina Martins; Sara S Dias; Gloria Nunes; Zelia Silva; Manuela Correia; Maria J Marques Gomes; Paula A Videira Journal: Clin Lung Cancer Date: 2013-07-22 Impact factor: 4.785
Authors: Yutao Li; Amit Sharma; Xiaolong Wu; Hans Weiher; Dirk Skowasch; Markus Essler; Ingo G H Schmidt-Wolf Journal: Front Oncol Date: 2022-05-11 Impact factor: 5.738